Projects per year
Abstract
Objective: To assessmyoepithelium with p63 in fresh breast cancer (BC)
tissue samples collected in RNA later for further analysis with Next
Generation Sequencing (NGS) technique. For a better understanding of
the NGS bulk-analysis, a central part of the sample in RNA-later is
formalin-fixed paraffin-embedded to score relative cellularity in % on
hematoxylin-eosin (HE) staining (% of invasive cancer, cancer in situ,
benign epithelium, lymphocytes and fat). Our aim is hence to test p63
immunohistochemistry (IHC) to highlight myoepithelium and to facilitate
the evaluation of the relative cellularity on BC-tissue pre-treated with
RNA-later.
Method: Two-hundred and twenty-four selected samples of fresh BC
tissue collected in RNA-later. A 10 mg central piece from each sample
was FFPE and assembled in a tissue-microarray (TMA) and sectioned to
HE and p63 IHC.
Results: All samples (n = 224) had internal control for myoepithelium
surrounding in situ cancer or benign epithelium. p63 showed positive
nuclear staining in myoepithelial cells in 92 % (206/224) of samples
and false negative p63 staining in 8 % (18/224).
Conclusion: p63 IHC is assessable in samples of FFPE BC-tissue pretreated
with RNA-later.
tissue samples collected in RNA later for further analysis with Next
Generation Sequencing (NGS) technique. For a better understanding of
the NGS bulk-analysis, a central part of the sample in RNA-later is
formalin-fixed paraffin-embedded to score relative cellularity in % on
hematoxylin-eosin (HE) staining (% of invasive cancer, cancer in situ,
benign epithelium, lymphocytes and fat). Our aim is hence to test p63
immunohistochemistry (IHC) to highlight myoepithelium and to facilitate
the evaluation of the relative cellularity on BC-tissue pre-treated with
RNA-later.
Method: Two-hundred and twenty-four selected samples of fresh BC
tissue collected in RNA-later. A 10 mg central piece from each sample
was FFPE and assembled in a tissue-microarray (TMA) and sectioned to
HE and p63 IHC.
Results: All samples (n = 224) had internal control for myoepithelium
surrounding in situ cancer or benign epithelium. p63 showed positive
nuclear staining in myoepithelial cells in 92 % (206/224) of samples
and false negative p63 staining in 8 % (18/224).
Conclusion: p63 IHC is assessable in samples of FFPE BC-tissue pretreated
with RNA-later.
Original language | English |
---|---|
Article number | E-PS-02-027 |
Pages (from-to) | 299 |
Number of pages | 1 |
Journal | Virchows Archiv |
Volume | 471 |
Issue number | Supplement 1 |
DOIs | |
Publication status | Published - 2017 Sept 2 |
Event | 29th European Congress of Pathology - RAI, Amsterdam, Netherlands Duration: 2017 Sept 2 → … Conference number: 29 |
Subject classification (UKÄ)
- Cancer and Oncology
Fingerprint
Dive into the research topics of 'Myoepithelium assessment with p63 immunostaining in formalinfixed paraffin-embedded breast cancer tissue pre-treated with RNA-later'. Together they form a unique fingerprint.Projects
- 1 Active
-
Sweden Cancerome Analysis Network - Breast (SCAN-B): a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
Borg, Å. (PI), Ehinger, A. (PI), Hegardt, C. (PI), Larsson, C. (PI), Loman, N. (PI), Malmberg, M. (PI), Ryden, L. (PI) & Saal, L. (PI)
Mrs. Berta Kamprad's Cancer Foundation
2009/06/01 → …
Project: Network
Activities
- 1 Participation in conference
-
29th European Congress of Pathology
Ehinger, A. (Participant)
2017 Sept 2 → 2017 Sept 6Activity: Participating in or organising an event › Participation in conference